Rhythm Pharmaceuticals, Inc. RYTM Net interest and investment income (loss)
Net interest and investment income (loss) at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s net interest and investment income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s net interest and investment income (loss)?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported net interest and investment income (loss) of $3.55M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s net interest and investment income (loss) changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s net interest and investment income (loss) decreased by 2.3% year-over-year, from $3.64M to $3.55M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s net interest and investment income (loss)?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s net interest and investment income (loss) has grown at a 141.9% compound annual growth rate (CAGR), from $447K to $15.29M.